Covidien, one of the world’s leading global providers of healthcare products, has announced the global launch of its V-Loc 90 device, the newest addition to its absorbable wound closure devices for knotless wounds. The product received clearance from the U.S. Food and Drug Administration on May 11, 2010 and is built on the success of the V-Loc 180 device that was launched in October 2009.
The V-Loc device helps close up wounds 50% faster than conventional sutures and without tying knots or changing any of the usual wound closure techniques and protocol.
The device works by holding the edges of the wound together tightly during the healing period. The V-Loc 90 device contains faster absorbing materials than other suture technologies, and in most cases, absorption is complete within 90 to 110 days.
According to Michel Therin, Vice President of the Soft Tissue Repair and Biosurgery division of Covidien, “With this new addition to our knotless wound closure portfolio, surgeons have an even broader array of choices for closing surgical incisions safely, quickly and effectively…the V-Loc 90 device is designed to provide better patient outcomes through the fast absorption of the product following the critical wound healing period after surgery.”
General surgeons, as well as plastic surgeons and cosmetic surgery professionals can all benefit from the V-Loc wound closure devices. The device is easy to handle and it produces targeted tension that can eliminate the need for another hand during the wound closing process. The device was previewed at the American Society for Aesthetic Plastic Surgery’s annual meeting in Washington, D.C. in April 2010. Many surgeons responded positively to the device’s ease of use and benefits, including the reduced operating time.
Covidien is a worldwide leader in manufacturing and distributing medical devices, pharmaceuticals and medical supplies, and currently sells products in over 140 countries.
(Source: Covidien Press Release)